Clinical Trial Update: MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia [Phase 4]

View source ↗

Summary

Phase 4 trial update reporting measurement of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1a IM, completed in Mexico and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Avonex (Interferon beta-1a)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis | Phase 4 | Status: COMPLETED